B cells are associated with survival and immunotherapy response in sarcoma
暂无分享,去创建一个
J. Wargo | C. Lucchesi | A. Reyniès | C. Sautès-Fridman | A. Lazar | J. Adam | H. Tawbi | E. Keung | F. Petitprez | W. Fridman | T. Chen | Cheng-ming Sun | J. Calderaro | Y. Jeng | Li-Ping Hsiao | L. Lacroix | A. Bougoüin | Marco Moreira | Guillaume Lacroix | Ivo Natario | Y. Laizet | M. Toulmonde | M. Burgess | V. Bolejack | D. Reinke | K. Wani | Wei-Lien Wang | A. Lazar | C. Roland | A. Italiano | W. Fridman | A. de Reyniès | Wei-Lien Wang | M. Moreira | Cheng-Ming Sun
[1] P. Meltzer,et al. Mechanisms of sarcoma development , 2003, Nature Reviews Cancer.
[2] G. Freeman,et al. Programmed Death-1 (PD-1) is a Marker of Germinal Center-associated T Cells and Angioimmunoblastic T-Cell Lymphoma , 2006, The American journal of surgical pathology.
[3] Cheng Li,et al. Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.
[4] Trevor Hastie,et al. Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling , 2009, Oncogene.
[5] Derek Y. Chiang,et al. Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy , 2010, Nature Genetics.
[6] Rafael A Irizarry,et al. Frozen robust multiarray analysis (fRMA). , 2010, Biostatistics.
[7] J. Blay,et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity , 2010, Nature Medicine.
[8] T. Yeatman,et al. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. , 2011, The American journal of pathology.
[9] F. Chibon,et al. New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics , 2011, The Journal of pathology.
[10] R. Sciot,et al. Mitotic Checkpoints and Chromosome Instability Are Strong Predictors of Clinical Outcome in Gastrointestinal Stromal Tumors , 2011, Clinical Cancer Research.
[11] Li-Xuan Qin,et al. Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis. , 2011, Cancer research.
[12] T. Dønnem,et al. Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas , 2012, BMC Clinical Pathology.
[13] P. Watson,et al. CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27− Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer , 2012, Clinical Cancer Research.
[14] T. Dønnem,et al. High expression of CD20+ lymphocytes in soft tissue sarcomas is a positive prognostic indicator , 2012, Oncoimmunology.
[15] Benjamin Haibe-Kains,et al. CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. , 2013, The Journal of clinical investigation.
[16] Olivier Delattre,et al. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] K. Jang,et al. Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas , 2013, PloS one.
[18] C. Sautès-Fridman,et al. Tertiary lymphoid structures in cancer and beyond. , 2014, Trends in immunology.
[19] N. Rioux-Leclercq,et al. Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting , 2015, Clinical Cancer Research.
[20] G. Freeman,et al. Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer , 2015, Clinical Cancer Research.
[21] Narasimhan P. Agaram,et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. , 2015, Human pathology.
[22] R. Boidot,et al. Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients , 2016, Oncoimmunology.
[23] B. Nelson,et al. Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer , 2016, Clinical Cancer Research.
[24] S. Paydaş,et al. Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas , 2016, Medical Oncology.
[25] L. Bixby,et al. A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases , 2016, Clinical Cancer Research.
[26] P. Laurent-Puig,et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.
[27] J. Blay,et al. PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas , 2017, Oncoimmunology.
[28] Y. Fujisawa,et al. Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma , 2017, Oncoimmunology.
[29] J. Crowley,et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. , 2017, The Lancet. Oncology.
[30] Robin L. Jones,et al. T‐cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death‐ligand 1 expression in patients with soft tissue sarcomas , 2017, Cancer.
[31] A. Reyniès,et al. Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies , 2018, Cancer Immunology, Immunotherapy.
[32] Steven J. M. Jones,et al. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas , 2017, Cell.
[33] B. Nelson,et al. Prognostic Significance of Tumor-Infiltrating B Cells and Plasma Cells in Human Cancer , 2018, Clinical Cancer Research.
[34] Holger Moch,et al. Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. , 2018, Cancer research.
[35] C. Antonescu,et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. , 2018, The Lancet. Oncology.
[36] R. Stupp,et al. Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer , 2017, Oncoimmunology.
[37] C. Sautès-Fridman,et al. Tertiary lymphoid structures in the era of cancer immunotherapy , 2019, Nature Reviews Cancer.
[38] H. Tawbi,et al. Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts. , 2019, Journal of Clinical Oncology.
[39] Impact of Aurora kinase A and B expression on response to neoadjuvant chemotherapy and patient outcome in muscle-invasive bladder cancer (MIBC). , 2019, Journal of Clinical Oncology.
[40] Jeffrey E. Lee,et al. B cells and tertiary lymphoid structures promote immunotherapy response , 2020, Nature.